Stockreport

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon e...

Adial Pharmaceuticals, Inc  (ADIL) 
US:NASDAQ Investor Relations: adialpharma.com
PDF Adial Pharmaceuticals, Inc The Collaboration Framework marks Adial's first step towards commercial partnership and establishing an exclusive European pathway as AD04 [Read more]